Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedMar 26, 2026
DataAggregated Company Financials
Companies14
  • 7D-0.7%
  • 3M4.5%
  • 1Y23.2%
  • YTDn/a

The Pharma is pretty flat in the last 7 days, but GSK has stood out, gaining 4.1%. The past year has been better, since the industry has gained 23% in that time. As for the next few years, earnings are expected to grow by 10% per annum.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 26 Mar 2026UK£337.4bUK£90.7bUK£15.7b19.4x21.6x3.7x
Sat, 21 Feb 2026UK£368.0bUK£90.2bUK£15.4b23.5x23.9x4.1x
Mon, 19 Jan 2026UK£329.1bUK£89.7bUK£14.6b21.3x22.5x3.7x
Wed, 17 Dec 2025UK£320.3bUK£89.5bUK£14.6b21.3x21.9x3.6x
Fri, 14 Nov 2025UK£321.4bUK£90.2bUK£14.7b22x21.8x3.6x
Sun, 12 Oct 2025UK£300.1bUK£88.0bUK£11.8b19.8x25.5x3.4x
Tue, 09 Sep 2025UK£282.9bUK£87.3bUK£11.7b22.3x24.2x3.2x
Thu, 07 Aug 2025UK£264.8bUK£87.9bUK£11.4b26.8x23.2x3x
Sat, 05 Jul 2025UK£257.7bUK£86.0bUK£10.6b25.8x24.4x3x
Mon, 02 Jun 2025UK£271.4bUK£86.5bUK£10.6b27.3x25.5x3.1x
Wed, 30 Apr 2025UK£263.6bUK£86.8bUK£10.1b26x26.1x3x
Fri, 28 Mar 2025UK£275.7bUK£87.7bUK£9.7b32x28.5x3.1x
Sun, 23 Feb 2025UK£283.5bUK£88.7bUK£9.4b30.9x30x3.2x
Tue, 21 Jan 2025UK£230.3bUK£76.3bUK£7.9b31.7x29.2x3x
Thu, 19 Dec 2024UK£222.2bUK£74.9bUK£7.7b31.4x28.8x3x
Sat, 16 Nov 2024UK£215.0bUK£75.2bUK£7.8b30x27.7x2.9x
Mon, 14 Oct 2024UK£250.3bUK£72.2bUK£9.0b31.1x27.7x3.5x
Wed, 11 Sep 2024UK£267.8bUK£72.2bUK£9.0b39.1x29.7x3.7x
Fri, 09 Aug 2024UK£267.4bUK£73.1bUK£9.1b38.7x29.5x3.7x
Sun, 07 Jul 2024UK£256.0bUK£71.2bUK£9.5b31.6x26.9x3.6x
Tue, 04 Jun 2024UK£264.4bUK£71.2bUK£9.5b31.2x27.7x3.7x
Thu, 02 May 2024UK£266.0bUK£72.2bUK£9.6b31.7x27.7x3.7x
Sat, 30 Mar 2024UK£245.1bUK£70.8bUK£9.7b31.8x25.2x3.5x
Mon, 26 Feb 2024UK£236.1bUK£70.6bUK£9.6b33.7x24.5x3.3x
Wed, 24 Jan 2024UK£236.8bUK£69.0bUK£10.7b36.2x22.2x3.4x
Fri, 22 Dec 2023UK£233.0bUK£69.0bUK£10.7b34.9x21.8x3.4x
Sun, 19 Nov 2023UK£227.8bUK£69.7bUK£10.8b53.8x21.2x3.3x
Tue, 17 Oct 2023UK£245.1bUK£70.6bUK£10.3b56.6x23.7x3.5x
Thu, 14 Sep 2023UK£237.8bUK£69.7bUK£10.2b53.5x23.2x3.4x
Sat, 12 Aug 2023UK£240.8bUK£69.1bUK£10.2b52.8x23.7x3.5x
Mon, 10 Jul 2023UK£223.4bUK£67.4bUK£7.8b52.7x28.5x3.3x
Wed, 07 Jun 2023UK£253.0bUK£68.7bUK£8.0b55.5x31.7x3.7x
Fri, 05 May 2023UK£256.8bUK£68.2bUK£7.9b55.7x32.3x3.8x
Sun, 02 Apr 2023UK£243.3bUK£69.5bUK£6.9b51.9x35.3x3.5x
Price to Earnings Ratio

35.3x


Total Market Cap: UK£243.3bTotal Earnings: UK£6.9bTotal Revenue: UK£69.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 26.2x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 21.6x which is lower than its 3-year average PE of 26.2x.
  • The industry is trading close to its 3-year average PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 32% per year over the last three years.
  • Revenues for these companies have grown 9.3% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does U.K. Pharma compare with similar industries?

GB Market-1.97%
Healthcare-0.93%
Pharma-0.69%
Pharma-0.69%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GSK GSKUK£20.544.1%
+UK£3.2b		39.2%PE14.4x
AGY Allergy TherapeuticsUK£0.101.0%
+UK£6.3m		61.5%PS12.1x
EAH ECO Animal Health GroupUK£0.981.6%
+UK£1.0m		67.5%PE22x
SAR Sareum HoldingsUK£0.173.1%
+UK£690.3k		37.5%PB19.1x
FUM Futura MedicalUK£0.0136.0%
+UK£418.6k		-87.5%PS0.9x

Latest News

HLN
UK£3.62
Haleon
7D
-6.3%
1Y
-5.3%

HLN: Execution And Cash Returns Will Support Future Re Rating Potential

Haleon's analyst price target has been nudged up from £5.10 to £5.12, reflecting analysts' updated assumptions for slightly higher revenue growth and profit margins, together with recent target increases and rating changes across several research houses. Analyst Commentary Recent Street research on Haleon has been active, with several bullish analysts adjusting their targets and ratings while one major European house turned more cautious.
FUM
UK£0.013
Futura Medical
7D
6.0%
1Y
-87.5%
IMM
UK£0.045
ImmuPharma
7D
-8.3%
1Y
42.6%
HCM
UK£2.06
HUTCHMED (China)
7D
-4.2%
1Y
-5.5%
HIK
UK£12.73
Hikma Pharmaceuticals
7D
-0.9%
1Y
-36.7%
EAH
UK£0.98
ECO Animal Health Group
7D
1.6%
1Y
67.5%
STX
UK£0.082
Shield Therapeutics
7D
-1.2%
1Y
187.7%

STX: Pediatric Label Expansion And Added Exclusivity Will Support Future Upside

Analysts have kept their fair value framework for Shield Therapeutics broadly unchanged, with a slightly adjusted profit margin outlook and future P/E assumption. These updates feed into a refreshed price target in £ terms that remains closely aligned with the prior figure.
GSK
UK£20.54
GSK
7D
4.1%
1Y
39.2%

GSK: Upgraded Fair Value Will Rely On Expanding Respiratory And Vaccine Portfolio

Analysts have raised the fair value estimate for GSK from £23.63 to £27.50. They attribute this change to recent upward revisions to Street price targets, along with updated assumptions that include slightly lower revenue growth, a higher discount rate, modestly stronger profit margins, and a marginally higher future P/E.
AZN
UK£140.62
AstraZeneca
7D
-1.5%
1Y
25.2%

AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating

Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.
SAR
UK£0.17
Sareum Holdings
7D
3.1%
1Y
37.5%
AGY
UK£0.10
Allergy Therapeutics
7D
1.0%
1Y
61.5%
ANCR
UK£2.43
Animalcare Group
7D
-7.6%
1Y
11.0%
POLB
UK£0.041
Poolbeg Pharma
7D
-4.1%
1Y
50.0%